Cargando…
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients
Relapsed/refractory primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) are associated with short survival and represent an unmet need, requiring novel effective strategies. Anti-CD19 chimeric antigen receptor (CAR) T cells, effective in systemic lar...
Autores principales: | Cook, Michael R., Dorris, C. Scott, Makambi, Kepher H., Luo, Yutong, Munshi, Pashna N., Donato, Michelle, Rowley, Scott, Saad, Ayman, Goy, Andre, Dunleavy, Kieron, Ali, Alaa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813524/ https://www.ncbi.nlm.nih.gov/pubmed/36260735 http://dx.doi.org/10.1182/bloodadvances.2022008525 |
Ejemplares similares
-
CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021) -
CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2021) -
Micro RNAs as a Diagnostic Marker between Glioma and Primary CNS Lymphoma: A Systematic Review
por: Dabbagh Ohadi, Mohammad Amin, et al.
Publicado: (2023) -
Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice
por: Mulazzani, Matthias, et al.
Publicado: (2019) -
CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)